针对介质蛋白-17作为纤维性疾病的新疗法选择
Margherita Sisto1, Sabrina Lisi1
1Department of Translational Biomedicine and Neuroscience (DiBraiN), Section of Human Anatomy and Histology, University of Bari "Aldo Moro", 70124 Bari, Italy.
Journal of clinical medicine
|January 11, 2024
概括
纤维化是器官衰竭的主要原因,与高水平的介质蛋白-17 (IL-17) 有关. 新的研究探索IL-17的表观遗传控制,以开发抗纤维菌疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
- 分子生物学分子生物学
背景情况:
- 纤维化是全球器官损伤和死亡的重要原因,通常源于慢性炎症.
- 目前,抗纤维素治疗选择有限,这凸显了尚未满足的医疗需求.
- 升高的介质蛋白-17 (IL-17) 水平越来越多地与慢性炎症相关,导致纤维化并发症和器官衰竭.
研究的目的:
- 审查目前对介质蛋白-17 (IL-17) 在纤维瘤疾病发展中的作用的理解.
- 要突出针对纤维化中的IL-17通路的治疗策略的最新进展.
- 探索表观遗传机制控制IL-17水平的潜力,用于抗纤维菌治疗.
主要方法:
- 文献综述侧重于IL-17在纤维化疾病中的作用.
- 对针对IL-17的治疗干预措施最近的研究分析.
- 检查影响IL-17表达在纤维化环境中的表观遗传机制.
主要成果:
- IL-17在各种纤维性疾病的发病过程中起着至关重要的作用.
- 新兴的研究重点是表观遗传修饰作为纤维化中IL-17的关键调节者.
- 针对IL-17信号通路,特别是通过表观遗传调制,显示出新型抗纤维菌疗法的前景.
结论:
- 了解IL-17信号通路对于开发有效的抗纤维菌策略至关重要.
- 表观遗传机制为IL-17驱动纤维化治疗干预提供了一个有希望的途径.
- 对IL-17及其表观遗传调节的进一步研究可能会在治疗纤维化疾病方面取得重大进展.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527


